CG Oncology, Inc. (NASDAQ:CGON) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $81.7273.

Several brokerages have weighed in on CGON. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Truist Financial reissued a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Wolfe Research began coverage on CG Oncology in a research note on Tuesday. They set a “peer perform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Monday.

CG Oncology Stock Up 2.3%

NASDAQ:CGON opened at $64.76 on Thursday. CG Oncology has a 52 week low of $23.65 and a 52 week high of $75.50. The business’s 50-day simple moving average is $67.20 and its two-hundred day simple moving average is $54.46. The stock has a market cap of $5.71 billion, a PE ratio of -27.79 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. Sell-side analysts anticipate that CG Oncology will post -2.89 earnings per share for the current fiscal year.

Insider Activity

In other CG Oncology news, Director James Mulay sold 15,600 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the completion of the transaction, the director owned 15,600 shares in the company, valued at $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CGON. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology during the fourth quarter valued at approximately $27,000. NFSG Corp purchased a new position in shares of CG Oncology during the first quarter valued at approximately $34,000. Strengthening Families & Communities LLC purchased a new position in shares of CG Oncology during the third quarter valued at approximately $40,000. Comerica Bank boosted its position in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Finally, Fifth Third Bancorp purchased a new position in shares of CG Oncology during the first quarter valued at approximately $74,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.